FDA Approved: DEXILANT — Supplemental Application (Takeda Pharmaceuticals America, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Dexilant (dexlansoprazole) submitted by Takeda, resulting in changes to the drug’s labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erosive Esophagitis
• Gastroesophageal Reflux Disease

Drugs mentioned

• Dexilant (dexlansoprazole)

Snippet

SUPPL AP for DEXILANT (DEXLANSOPRAZOLE)